Atlas Trials

An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.

Clinical trial NCT01332513 · COMPLETED

Trial details

NCT number
NCT01332513
Sponsor
GlaxoSmithKline
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Epilepsy
Start date
2011-02-10
Primary completion
2011-05-23
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.